- Partnering with cross functional teams to develop strategic clinical development options- Facilitating the assessment of key risks, evaluating portfolio context, crafting clinical and commercial value story, and building valuation models & other relevant analyses for investment decisions- Lead cross-functional scenario planning to prepare for high-profile clinical trial readouts and enable high-quality & timely decision-making- Guide teams through governance processes to ensure that decisions are made in an efficient manner- Working with senior management to assign a prioritization to pipeline projects - Support the development and implementation of disease area strategies- Support due diligences and pre-due diligences of licensing / M&A opportunities by assessing strategic fit with our portfolio and disease area strategies'Stretch Assignment: Leading commercial evaluation & development team planning for the development of a subcutaneous formulation / device combination for a priority pipeline molecule.

As a Portfolio Leader, I provide an objective view to investment decision making processes and drive forward longer-term Disease Area Strategies.Therapeutic areas of focus include HR+ Breast Cancer, non-malignant haematology, & stroke. Key pipeline teams supported include giredestrant, inavolisib, crovalimab, emicizumab (Hemlibra), NXT007 and lytics teams.

Managing the collection and analysis of competitive insights as a strategic partner to global stakeholders across the lung cancer & tumour-agnostic portfolios.Actively contributing to the development of competitive strategies for late stage pipeline assets and marketed products in NSCLC (targeted therapies and immunotherapy), SCLC, & tumour-agnostic indications.Competitive Intelligence lead for the Tiragolumab program, helping to guide commercial and clinical development strategy to maximize value.Leading cross-functional workshops to inform disease area leads, global lifecycle teams and development teams of short-term and long-term competitive threat assessments.Maintaining strong relationships across the broader organisation to ensure competitive intelligence cascades through different functional departments to inform multiple decision points.Coordinating and leading medical congress coverage to ensure stakeholders are kept abreast of impactful competitor clinical data.Managing external agencies to ensure competitive intelligence research is impactful and can drive business decisions.Stretch Assignments: - Led a cross-functional team to evaluate the impact of lung cancer screening technologies & their impact on addressable populations in the future. All current & future business case assessments in lung cancer leverage the epidemiology assumptions derived by this team.- Led scenario planning for the readout of SKYSCRAPER-02 (pivotal tiragolumab study in ES-SCLC). I enagaged with key global affiliates and expert functions to outline commercial/medical/communications implications for different readout scenarios from the first pivotal SKYSCRAPER study. All future scenario planning efforts for the tiragolumab program leveraged the same framework.- Access strategy assessment for a partnering opportunity in the IBD space.